239 related articles for article (PubMed ID: 16960471)
21. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
[TBL] [Abstract][Full Text] [Related]
22. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study.
Woods SW; Saksa JR; Baker CB; Cohen SJ; Tek C
J Clin Psychiatry; 2008 Apr; 69(4):546-54. PubMed ID: 18312060
[TBL] [Abstract][Full Text] [Related]
23. Levetiracetam in the treatment of antipsychotics-resistant Tourette syndrome.
Oulis P; Karapoulios E; Masdrakis VG; Kouzoupis AV; Karakatsanis NA; Papageorgiou C; Papadimitriou GN; Soldatos CR
World J Biol Psychiatry; 2008; 9(1):76-7. PubMed ID: 17853302
[TBL] [Abstract][Full Text] [Related]
24. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia.
Damier P; Thobois S; Witjas T; Cuny E; Derost P; Raoul S; Mertens P; Peragut JC; Lemaire JJ; Burbaud P; Nguyen JM; Llorca PM; Rascol O;
Arch Gen Psychiatry; 2007 Feb; 64(2):170-6. PubMed ID: 17283284
[TBL] [Abstract][Full Text] [Related]
25. Ten year outcome of tardive dyskinesia during continuous treatment with first generation antipsychotics.
Rittmannsberger H
Psychiatr Danub; 2008 Dec; 20(4):461-5. PubMed ID: 19011586
[TBL] [Abstract][Full Text] [Related]
26. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group.
van Os J; Walsh E; van Horn E; Tattan T; Bale R; Thompson SG
Acta Psychiatr Scand; 2000 Apr; 101(4):300-6. PubMed ID: 10782550
[TBL] [Abstract][Full Text] [Related]
27. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.
Zhang XY; Zhou DF; Cao LY; Xu CQ; Chen DC; Wu GY
J Clin Psychopharmacol; 2004 Feb; 24(1):83-6. PubMed ID: 14709952
[TBL] [Abstract][Full Text] [Related]
28. Levetiracetam is not effective for essential tremor.
Elble RJ; Lyons KE; Pahwa R
Clin Neuropharmacol; 2007; 30(6):350-6. PubMed ID: 18090460
[TBL] [Abstract][Full Text] [Related]
29. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients.
Stedman TJ; Whiteford HA; Eyles D; Welham JL; Pond SM
J Clin Psychopharmacol; 1991 Feb; 11(1):43-7. PubMed ID: 1674950
[TBL] [Abstract][Full Text] [Related]
30. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study.
Striano P; Manganelli F; Boccella P; Perretti A; Striano S
Mov Disord; 2005 Dec; 20(12):1610-4. PubMed ID: 16078205
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of levetiracetam in Huntington disease.
de Tommaso M; Di Fruscolo O; Sciruicchio V; Specchio N; Cormio C; De Caro MF; Livrea P
Clin Neuropharmacol; 2005; 28(6):280-4. PubMed ID: 16340384
[TBL] [Abstract][Full Text] [Related]
32. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease.
Bedlack RS; Pastula DM; Hawes J; Heydt D
Amyotroph Lateral Scler; 2009 Aug; 10(4):210-5. PubMed ID: 18821142
[TBL] [Abstract][Full Text] [Related]
33. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of levetiracetam for outpatient alcohol detoxification.
Müller CA; Schäfer M; Schneider S; Heimann HM; Hinzpeter A; Volkmar K; Förg A; Heinz A; Hein J
Pharmacopsychiatry; 2010 Jul; 43(5):184-9. PubMed ID: 20503149
[TBL] [Abstract][Full Text] [Related]
35. Adjunctive levetiracetam in infants and young children with refractory partial-onset seizures.
Piña-Garza JE; Nordli DR; Rating D; Yang H; Schiemann-Delgado J; Duncan B;
Epilepsia; 2009 May; 50(5):1141-9. PubMed ID: 19243423
[TBL] [Abstract][Full Text] [Related]
36. [Tardive dyskinesia: pergolid, a possible therapeutic option].
Diehl A; Braus DF; Büchel C; Krumm B; Medori R; Gattaz WF
Psychiatr Prax; 2003 Sep; 30(6):333-7. PubMed ID: 12970819
[TBL] [Abstract][Full Text] [Related]
37. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial.
Levisohn PM; Mintz M; Hunter SJ; Yang H; Jones J;
Epilepsia; 2009 Nov; 50(11):2377-89. PubMed ID: 19702752
[TBL] [Abstract][Full Text] [Related]
38. Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome.
Awaad Y; Michon AM; Minarik S
Mov Disord; 2005 Jun; 20(6):714-8. PubMed ID: 15704204
[TBL] [Abstract][Full Text] [Related]
39. Levetiracetam in L-dopa-induced dyskinesia.
Meco G; Fabrizio E; Epifanio A; Di Raimondo G; Vanacore N; Morgante L
Clin Neuropharmacol; 2005; 28(2):102-3. PubMed ID: 15795556
[No Abstract] [Full Text] [Related]
40. Clinical and familial correlates of tardive dyskinesia in India and Israel.
Bhatia T; Sabeeha MR; Shriharsh V; Garg K; Segman RH; Uriel HL; Strous R; Nimgaonkar VL; Bernard L; Deshpande SN
J Postgrad Med; 2004; 50(3):167-72; discussion 172. PubMed ID: 15377799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
